260 related articles for article (PubMed ID: 22349185)
1. Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.
Selbo PK; Weyergang A; Eng MS; Bostad M; Mælandsmo GM; Høgset A; Berg K
J Control Release; 2012 Apr; 159(2):197-203. PubMed ID: 22349185
[TBL] [Abstract][Full Text] [Related]
2. Development of resistance to photodynamic therapy (PDT) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming PDT-resistance.
Olsen CE; Weyergang A; Edwards VT; Berg K; Brech A; Weisheit S; Høgset A; Selbo PK
Biochem Pharmacol; 2017 Nov; 144():63-77. PubMed ID: 28784290
[TBL] [Abstract][Full Text] [Related]
3. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization.
Berg K; Nordstrand S; Selbo PK; Tran DT; Angell-Petersen E; Høgset A
Photochem Photobiol Sci; 2011 Oct; 10(10):1637-51. PubMed ID: 21773635
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
[TBL] [Abstract][Full Text] [Related]
5. The photosensitizer disulfonated aluminum phthalocyanine reduces uptake and alters trafficking of fluid phase endocytosed drugs in vascular endothelial cells--impact on efficacy of photochemical internalization.
Vikdal M; Generalov R; Berg K
Biochem Pharmacol; 2013 Sep; 86(6):748-58. PubMed ID: 23876343
[TBL] [Abstract][Full Text] [Related]
6. Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.
Morgan J; Jackson JD; Zheng X; Pandey SK; Pandey RK
Mol Pharm; 2010 Oct; 7(5):1789-804. PubMed ID: 20684544
[TBL] [Abstract][Full Text] [Related]
7. ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
Abdel Gaber SA; Müller P; Zimmermann W; Hüttenberger D; Wittig R; Abdel Kader MH; Stepp H
J Photochem Photobiol B; 2018 Jan; 178():182-191. PubMed ID: 29156346
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2.
Pan L; Lin H; Tian S; Bai D; Kong Y; Yu L
Lasers Surg Med; 2017 Sep; 49(7):719-726. PubMed ID: 28370217
[TBL] [Abstract][Full Text] [Related]
9. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.
Robey RW; Steadman K; Polgar O; Bates SE
Cancer Biol Ther; 2005 Feb; 4(2):187-94. PubMed ID: 15684613
[TBL] [Abstract][Full Text] [Related]
10. Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.
Berstad MB; Weyergang A; Berg K
Biochim Biophys Acta; 2012 Dec; 1820(12):1849-58. PubMed ID: 22981913
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
12. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.
Jung KA; Choi BH; Kwak MK
Mol Pharmacol; 2015; 87(3):465-76. PubMed ID: 25534417
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
15. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
16. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
17. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
18. Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.
Baglo Y; Liang BJ; Robey RW; Ambudkar SV; Gottesman MM; Huang HC
Cancer Lett; 2019 Aug; 457():110-118. PubMed ID: 31071369
[TBL] [Abstract][Full Text] [Related]
19. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Elkind NB; Szentpétery Z; Apáti A; Ozvegy-Laczka C; Várady G; Ujhelly O; Szabó K; Homolya L; Váradi A; Buday L; Kéri G; Német K; Sarkadi B
Cancer Res; 2005 Mar; 65(5):1770-7. PubMed ID: 15753373
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
